With this program, the professional will be able to integrate the latest advances in Big Data applied to pulmonology into their daily work, while deepening their knowledge of techniques such as pulmonary nodule volumetry" 

Pulmonology is one of the clinical disciplines that has experienced the greatest advances in recent years. Areas such as Big Data have led to the emergence of new techniques in this field, making it more accurate and effective. Therefore, the specialist has the opportunity to incorporate the latest procedures into their work thanks to this Advanced Master's Degree, which also integrates specialties such as genomic precision pulmonology. 

Therefore, throughout this program, the physician will be able to delve into issues such as the genetics of susceptibility to lung cancer, the genetic links of COPD, pulmonary eosinophilias associated with asthma or hypoventilation syndromes. In addition, you will learn about the latest advances in procedures such as electromagnetic navigation or medical thoracoscopy. This will give you access to the most cutting-edge innovations in this complex but exciting field. 

This Advanced Master's Degree is developed through a 100% online teaching method that has been specially designed with the working professional in mind, as it adapts to their personal circumstances, adjusting to their work pace and without imposing fixed schedules. In addition, its innovative contents will be presented in multimedia format, taught by a teaching staff of great prestige in this medical area. 

TECH online methodology will allow you to combine your work with your studies, since it is completely adapted to you, without imposing fixed schedules” 

This Advanced master’s degree in Clinical Pulmonology contains the most complete and up-to-date scientific program on the market. The most important features include: 

• Practical cases presented by experts in medicine 
• The graphic, schematic, and eminently practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where self-assessment can be used to improve learning
• Special emphasis is placed on innovative methodologies in the management of pneumologic pathologies
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

TECH provides you with state-of-the-art educational technology: interactive summaries, case studies, video proceedings, master classes, etc. The most varied and effective resources to get you up to date" 

The teaching staff includes professionals from the psychology sector, who bring their experience to this training program, as well as renowned specialists from leading societies and prestigious universities. 

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide an immersive training experience designed to train for real-life situations. 

This program is designed around Problem Based Learning, whereby the student must try to solve the different professional practice situations that arise during the academic year. For this purpose, the professional will be assisted by an innovative interactive video system created by renowned and experienced experts.

You will deepen you knowledge in the latest advances in the genetic links of COPD and in the surgical technique for lung transplants"

This Advanced Master's Degree will allow you to integrate the most recent innovations in pulmonology into your daily qoek in a quick and comfortable way"

This Advanced master’s degree in Clinical Pulmonology has been designed by leading internationally-recognised specialists who have structured the program into 20 specific modules. Throughout these modules, the professional will learn about the latest advances in issues such as late complications of lung transplantation, management of alpha-1 antitrypsin deficiency, respiratory involvement of sickle cell disease or anti-IL-9 antibodies, anti-TNF alpha, anti T-lymphocytes in asthma. 

The most complete and up-to-date content in Clinical Pulmonology is now available to you"  

Module 1. Interstitial Lung Diseases

1.1. ILD's

1.1.1. Classification and Epidemiology of ILD's
1.1.2. Diagnostic Approximation

1.1.2.1. Medical History. Physical Exploration
1.1.2.2. Clinical Laboratory and Pulmonary Function Laboratory
1.1.2.3. Radiodiagnosis: Chest Radiography HRCT. Radiological Patterns
1.1.2.4. Invasive Techniques: Bronchoalveolar Lavage (BAL), Transbronchial Biopsy (TBB) and
             Cryobiopsy. Surgical Biopsy. Indications and Pathologic Patterns
1.1.2.5. Multidisciplinary Diagnosis

1.1.3. Cellular Aging, Genetics and Biomarkers in ILD

1.1.3.1. Pathogenesis of Cellular Aging
1.1.3.2. Characteristics, Prognostic Value and Treatment of Telomeric Alterations
1.1.3.3. Familial Pulmonary Fibrosis. Biomarkers. Diagnostic, Prognostic and Therapeutic Use

1.2.     Idiopathic Pulmonary Fibrosis

1.2.1. Epidemiology
1.2.2. Risk factors
1.2.3. Natural History and Prognosis
1.2.4. Diagnostic Approximation

1.2.4.1. Clinical Manifestations Physical Exploration
1.2.4.2. Radiological Criteria
1.2.4.3. Histopathological Criteria
1.2.4.4. Useful Biomarkers in IPF

1.2.5. Treatment
1.2.6. Exacerbation of IPF

1.3.     Idiopathic Non-specific Interstitial Pneumonia (NSIP) ILD Associated With Systemic Autoimmune Diseases (I): ILD Associated with Rheumatoid Arthritis (RA-ILD) and ILD associated with Systemic Sclerosis (SSc-IDP)

1.3.1. Idiopathic NSIP

1.3.1.1. Histopathological Forms
1.3.1.2. Diagnostic Tests
1.3.1.3. Treatment
1.3.1.4. Prognosis

1.3.2. ILD Associated With Systemic Autoimmune Diseases

1.3.2.1. RA-ILD
1.3.2.2. SSc-ILD

1.4. ILD Associated With Systemic Autoimmune Diseases (II)

1.4.1. Dermatosis/Polymyositis
1.4.2. Sjögren's Syndrome
1.4.3. Mixed Connective Tissue Disease. “Overlap” Syndrome
1.4.4. Interstitial Pneumonia with Autoimmune Features (IPAF)

1.5. Sarcoidosis

1.5.1. Pathophysiology.
1.5.2. Histology
1.5.3. Diagnostic Approximation
1.5.4. Evolution and Prognosis
1.5.5. Treatment

1.6. Hypersensitivity Pneumonitis

1.6.1. Etiology
1.6.2. Pathophysiology.
1.6.3. Classification. Clinical Forms
1.6.4. Diagnostic Criteria. Differential Diagnosis
1.6.5. Natural History and Prognosis
1.6.6. Treatment

1.7. Cystic Pulmonary Diseases

1.7.1. Lymphangioleiomyomatosis (LAM)

1.7.1.1. Clinical Manifestations
1.7.1.2. Diagnostic Approximation
1.7.1.3. Treatment

1.7.2. Langerhans Cell Histiocytosis(HPCL)

1.7.2.1. Clinical Manifestations
1.7.2.2. Diagnostic Approximation
1.7.2.3. Treatment

1.7.3. Lymphocytic Interstitial Pneumonia (LIP)

1.7.3.1. Clinical Manifestations
1.7.3.2. Diagnostic Approximation
1.7.3.3. Treatment

1.8. Cryptogenic Organizing Pneumonia (COP)

1.8.1. Pathogenesis
1.8.2. Clinical Manifestations
1.8.3. Radiological Patterns
1.8.4. Diagnostic Approximation
1.8.5. Natural History
1.8.6. Treatment

1.9. Work and Occupational Diseases

1.9.1. Diseases Related to Asbestos

1.9.1.1. Varieties of Asbestos. Sources of Exposure
1.9.1.2. Pleural Fibrosis. Clinical Forms and Radiological Diagnosis
1.9.1.3. Asbestosis. Clinical and Radiological Findings, Diagnostic Criteria and Treatment

1.9.2. Silicosis
1.9.3. Coal Pneumoconiosis

1.10.     Pulmonary Eosinophilias. ILD Associated With Drugs. Other Rare ILDs: Pleuropulmonary Fibroelastosis. Alveolar Microlithiasis. Alveolar Proteinosis

1.10.1. Acute Eosinophilic Pneumonia

1.10.1.1. Epidemiology and Risk Factors
1.10.1.2. Pathogenesis
1.10.1.3. Clinical, Radiological, Functional and Anatomopathological Diagnosis
1.10.1.4. Treatment

1.10.2. ILD Associated With Drugs

1.10.2.1. Epidemiology
1.10.2.2. Pathogenesis and Risk Factors
1.10.2.3. Diagnostic Approximation
1.10.2.4. Main Causative Agents

1.10.3. Differential Diagnosis of Pulmonary Eosinophilias
1.10.4. Other Rare ILDs: Pleuropulmonary Fibroelastosis, Alveolar Microlithiasis and Alveolar Proteinosis:
            Diagnostic Approximation, Evolution and Treatment

Module 2. Chronic Obstructive Pulmonary Disease

2.1. Etiopathogenesis

2.1.1. Epidemiology
2.1.2. Risk Factors
2.1.3. Pathogenesis

2.2. Pathophysiology of COPD and Clinical Presentation

2.2.1. Pathophysiology
2.2.2. Clinical Manifestations

2.3. Diagnosis and Characterization 

2.3.1. Diagnosis: Medical History, Physical Examination, Imaging Tests, Clinical Analysis and Functional Respiratory Examination
2.3.2. Characterization

2.3.2.1. By Severity of the Pulmonary Obstruction
2.3.2.2. By Clinical Type: Emphysema and Chronic Bronchitis
2.3.2.3. By Exacerbation Risk
2.3.2.4. By Symptoms

2.4. Pharmacological Treatment of Maintenance

2.4.1. Treatment Objectives
2.4.2. Drugs

2.4.2.1. Inhaled Treatment

2.4.2.1.1. Bronchodilators
2.4.2.1.2. Inhaled Corticosteroids

2.4.2.2. Oral Treatment

2.4.2.2.1. Theophylline
2.4.2.2.2. Roflumilast
2.4.2.2.3. Azithromycin

2.5. Smoking Management in COPD

2.5.1. Epidemiology
2.5.2. Diagnosis of Smoking in COPD
2.5.3. Non-Pharmacological Therapeutic Interventions
2.5.4. Pharmacological Therapeutic Interventions

2.6. Non-Pharmacological Treatment

2.6.1. Oxygen Therapy and NIMV
2.6.2. Vaccines
2.6.3. Nutrition
2.6.4. Palliative Treatment of Dyspnea
2.6.5. Reduction of Pulmonary Volume Due to Broncoscopy
2.6.6. Surgery: Reduction of Volume and Pulmonary Transplant

2.7. Exacerbation of COPD

2.7.1. Etiology and Pathogenesis
2.7.2. Classification of Severity
2.7.3. Treatment

2.8. Comorbidities

2.8.1. Prevalence
2.8.2. Impact on Mortality
2.8.3. Screening and Management

2.9. Rehabilitation and Physical Activity in COPD

2.9.1. Rehabilitation in COPD

2.9.1.1. Benefits
2.9.1.2. Indications
2.9.1.3. Structure of a Rehabilitation Project
2.9.1.4. Rehabilitation After the Exacerbation of COPD
2.9.1.5. Special Situations

2.9.2. Physical Activity

2.9.2.1. Measurement
2.9.2.2. Interventions

Module 3. Asthma

3.1. Etiopathogenesis

3.1.1. Epidemiology
3.1.2. Risk Factors
3.1.3. Pathogenesis

3.2. Diagnosis

3.2.1. Clinical Symptoms
3.2.2. Spirometry and Bronchodilator Test
3.2.3. Bronchial Provocation Tests
3.2.4. Determination of FeNO
3.2.5. Induced Sputum
3.2.6. Electronic Nose 
3.2.7. Volatile Organic Compounds in Exhaled Air
3.2.8. Diagnostic Algorithm

3.3. Classification of the Control and Severity

3.3.1. Control
3.3.2. Severity

3.4. Treatment of Maintenance

3.4.1.Treatment Objectives
3.4.2. Drugs:
3.4.3. Step Treatment
3.4.4. Allergen and Environmental Avoidance
3.4.5. Education and Written Action Plans

3.5. Treatment of Asthma Attacks

3.5.1. Risk Factors
3.5.2. Severity Assessment
3.5.3. Treatment According to Severity
3.5.4. High Emergency Criteria
3.5.5. Criteria for Hospitalization
3.5.6. Criteria for Discharge After Hospitalization
3.5.7. Outpatient Monitoring After the Attack

3.6. Uncontrolled Severe Asthma

3.6.1. Epidemiology
3.6.2. Diagnostic Procedure
3.6.3. Phenotypes of Severe Asthma
3.6.4. Treatment Algorithm

3.7. Occupational Asthma

3.7.1. Causative Agents
3.7.2. Classification
3.7.3. Diagnosis
3.7.4. Treatment
3.7.5. Asthma Worsened by Work

3.8. Nasal Pathology Associated with Asthma

3.8.1. Rhinitis

3.8.1.1. Diagnosis
3.8.1.2. Classification
3.8.1.3. Treatment

3.8.2. Rhinosinusitis and Nasal Polyposis

3.8.2.1. Diagnosis
3.8.2.2. Treatment

3.9. Pulmonary Eosinophilias Associated With Asthma

3.9.1. Acute Eosinophilic Pneumonia
3.9.2. Allergic Bronchopulmonary Aspergillosis
3.9.3. Eosinophilic Granulomatosis with Polyangiitis

3.10. Special Situations

3.10.1. Asthma and COPD Overlap (ACOS)
3.10.2. Respiratory Disease Exacerbated by Acetylsalicylic Acid
3.10.3. Asthma and Pregnancy
3.10.4. Exercise-Induced Asthma
3.10.5. Pseudo Asthmas
 

Module 4. Respiratory Infections and Related Diseases

4.1. Community-Acquired Pneumonia (CAP)

4.1.1. Epidemiology
4.1.2. Risk Factors
4.1.3. Comorbidities and Risk of CAP
4.1.4. Etiology
4.1.5. Clinical manifestations
4.1.6. Diagnosis
4.1.7. Assessmeant of the Severity of the CAP
4.1.8. Treatment
4.1.9. Clinical Response
4.1.10. Complications
4.1.11. Prevention: Vaccination

4.2. Nosocomial Pneumonia (Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia)

4.2.1. Pathogenesis.
4.2.2. Risk factors
4.2.3. Intrahospital Pneumonia
4.2.4. Pneumonia Associated with Mechanical Ventilation
4.2.5. Etiology
4.2.6. Diagnosis
4.2.7. Treatment
4.2.8. Preventive Measures

4.3. Pulmonary Abscess

4.3.1. Pathogenesis
4.3.2. Differences with Necrotizing Pneumonia
4.3.3. Microbiology
4.3.4. Clinical manifestations
4.3.5. Diagnosis
4.3.6. Differential Diagnosis
4.3.7. Treatment

4.4. Coronavirus: COVID-19

4.4.1. The 2019 Pandemic
4.4.2. Epidemiology
4.4.3. Pathogenesis
4.4.4. Clinical Symptoms
4.4.5. Diagnosis
4.4.6. Treatment
4.4.7. Complications
4.4.8. Prevention

4.4.8.1. Hygienic Measures and Social Distancing
4.4.8.2. Vaccines

4.5. Non-Cystic Fibrosis Bronchiectasis

4.5.1. Epidemiology and Costs
4.5.2. Pathophysiology
4.5.3. Etiology
4.5.4. Diagnosis
4.5.5. Differential Diagnosis
4.5.6. Microbiology
4.5.7. Severity and Prognostic Factors
4.5.8. Treatment
4.5.9. Monitoring
4.5.10. Consensus Treatment of CBI in COPD and Bronchiectasis

4.6. Cystic fibrosis

4.6.1. Aetiopathogenesis.
4.6.2. Epidemiology
4.6.3. Clinical manifestations
4.6.4. Diagnosis
4.6.5. Quality of Life Related to Health
4.6.6. Treatment

4.6.6.1. Of Exacerbation
4.6.6.2. Of Chronic Bronchial Infection
4.6.6.3. Of Bronchial Inflammation
4.6.6.4. Of Mucociliary Clearance
4.6.6.5. New Drugs (CFRT Protein Repairers)

4.6.7. Rehabilitation
4.6.8. Nutritional Treatment
4.6.9. Treating Complications

4.7. Pulmonary Tuberculosis: Epidemiology, Clinical Symptoms, Diagnosis, Complications and Prognosis

4.7.1. Epidemiology
4.7.2. Etiology
4.7.3. Pathogenesis and Pathophysiology
4.7.4. Clinical Manifestations
4.7.5. Diagnosis. Concept of Infection and Tuberculous Disease

4.7.5.1. Tuberculous Infection
4.7.5.2. Tuberculous Disease

4.7.5.2.1. Clinical and Radiological Diagnosis
4.7.5.2.2. Anatomical and Pathological Diagnosis
4.7.5.2.3. Microbiological Diagnosis

4.7.6. Complications and Prognosis

4.8. Pulmonary Tuberculosis: Treatment. Chemoprophylaxis

4.8.1. Types of Bacillary Populations
4.8.2. Standard Treatment. Appropriate Selection of Drug Combinations
4.8.3. Treatment in Special Situations

4.8.3.1. Immunodeficiencies
4.8.3.2. Pregnancy and Breastfeeding
4.8.3.3. Advanced Chronic Liver Failure
4.8.3.4. Advanced Chronic Kidney Disease

4.8.4. Adverse Effects
4.8.5. Interrupting the Treatment
4.8.6. Resistance
4.8.7. Chemoprophylaxis. Treatment of Latent Tuberculous Infection
4.8.8. Therapeutic Schemes for the Treatment of Multidrug-Resistant or Extensively Resistant Pulmonary TB

4.9. Atypical Mycobacteria

4.9.1. Taxonomy and Epidemiology
4.9.2. Pathogenesis and Susceptibility of the Host
4.9.3. Clinical Forms
4.9.4. Diagnostic Criteria for Atypical Mycobacterial Disease
4.9.5. Treatment

4.10. Pulmonary Aspergillosis and Other Mycoses

4.10.1. Pulmonary Aspergillosis
4.10.2. Candidiasis Broncopulmonar
4.10.3. Cryptococcosis
4.10.4. Mucormycosis
4.10.5. Pneumocystis

Module 5. Bronchopulmonary Neoplasms

5.1. Epidemiology

5.1.1. Incidence and Prognosis of Lung Cancer
5.1.2. Risk Factors: Tabacco, Jobs, Other Carcinogens
5.1.3. Screening

5.2. Solitary Pulmonary Nodule

5.2.1. Etiology
5.2.2. Factors Associated With Malignancy

5.2.2.1. Estimation of Malignancy
5.2.2.2. Sequential Evaluation. Management Algorithm

5.3. Classification

5.3.1. Histological Subtypes

5.3.1.1. Non-Small Cell: Adenocarcinoma, Epidermoid, Large Cell
5.3.1.2. Small Cell

5.3.2. Biomarkers with Diagnostic and Therapeutic Value

5.4. Diagnosis

5.4.1. Symptoms and Signs

5.4.1.1. Paraneoplastic Syndromes

5.4.2. Radiodiagnostics
5.4.3. Invasive Diagnostic Methods

5.5. Staging

5.5.1. General Aspects
5.5.2. TNM 8th Edition Classification

5.6. Multidisciplinary Evaluation in the Therapeutic Approach

5.6.1. Operability Criteria
5.6.2. Resectability Criteria

5.6.2.1. Resectable
5.6.2.2. Unresectable
5.6.2.3. Potentially Resectable

5.7. Treatment in Initial Stages

5.7.1. Surgical Management

5.7.1.1. Lobectomy and Lymphadenectomy
5.7.1.2. Pneumonectomy
5.7.1.3. Atypical Resections

5.7.2. Adjuvants

5.8. Locally Advanced Disease Treatment

5.8.1. Neoadjuvant
5.8.2. Radical Treatment with Chemoradiotherapy

5.9. Advanced Disease

5.9.1. Oligometastatic Disease
5.9.2. Chemotherapy
5.9.3. Immunotherapy
5.9.4. Directed Treatment

5.10. Support Treatments

5.10.1. Radiotherapy
5.10.2. Management of Complications Related to the Airway: Dyspnea, Superior Vena Cava Syndrome, Hemoptysis,
            Endobronchial Resection
5.10.3. Other Complications 

Module 6. Diseases of the Pleura and Mediastinum

6.1. Pleura

6.1.1. Anatomy
6.1.2. Histology

6.2. Pathophysiology of the Pleura

6.2.1. Pleural Pressure
6.2.2. Formation of Pleural Fluid
6.2.3. Absorption of Pleural Fluid 

6.3. Definition and Epidemiology of Pleural Diseases

6.3.1. Pleural Effusion
6.3.2. Hemothorax
6.3.3. Chylothorax
6.3.4. Pneumothorax
6.3.5. Solid Pleural Pathology

6.4. Clinical Diagnosis of Pleural Pathology

6.4.1. Symptoms
6.4.2. Physical Exploration

6.5. Imaging Diagnosis of Pleural Pathology

6.5.1. Chest X-ray
6.5.2. Chest CAT Scan
6.5.3. Thoracic Ultrasound Scan

6.6. Invasive Techniques for the Diagnosis of Pleural Effusion

6.6.1. Diagnostic Thoracentesis
6.6.2. Closed Pleural Biopsy
6.6.3. Medical Thoracoscopy

6.7. Solid Pleural Pathology

6.7.1. Pleural Fibrous Tumor
6.7.2. Pleural Pathology Due to Asbestos
6.7.3. Mesothelioma
6.7.4. Metastatic Cancer

6.8. Management of the Patient with Pleural Effusion

6.8.1. Diagnostic Approximation
6.8.2. Etiological Diagnosis
6.8.3. Treatment

6.9. Caring for a Patient with Pneumothorax

6.9.1. Classification
6.9.2. Diagnosis
6.9.3. Treatment

6.10. Mediastinal Diseases

6.10.1. Anatomy
6.10.2. Epidemiology
6.10.3. Mediastinitis
6.10.4. Mediastinal Tumors
6.10.5. Diagnostic Approximation of a Mediastinal Mass

Module 7. Pulmonary Circulation

7.1. Pathophysiology of Pulmonary Circulation

7.1.1. Anatomical-Functional Review
7.1.2. Physiological Changes with Age and Exercise
7.1.3. Pathophysiology

7.2. Acute Pulmonary Thromboembolism

7.2.1. Epidemiology and Etiopathogenesis of an Acute Pulmonary Thromboembolism
7.2.2. Clinical Presentation and Probability
7.2.3. Diagnosis of a Pulmonary Embolism
7.2.4. Prognostic Stratification

7.3. Therapeutic Management of Acute Pulmonary Thromboembolism

7.3.1. Treatment of Acute Pulmonary Thromboembolism
7.3.2. Prophylaxis of Venous Thromboembolic Disease
7.3.3. Pulmonary Embolism in Special Situations

7.3.3.1. Pulmonary Embolism in Oncologic Patients
7.3.3.2. Pulmonary Embolism in Pregnant Women

7.4. Pulmonary Arterial Hypertension

7.4.1. Epidemiology
7.4.2. Diagnosis and Clinical Assessment of Pulmonary Hypertension

7.5. Classification and Types of Pulmonary Hypertension

7.5.1. ERS/ESC Classification of Pulmonary Hypertension 
7.5.2. Group 1- Pulmonary Arterial Hypertension

7.5.2.1. Pulmonary Veno-Occlusive Disease/Pulmonary Capillary Hemangiomatosis
7.5.2.2. Persistent Pulmonary Hypertension of a Newborn

7.5.3. Group 2 - Pulmonary Hypertension Secondary to Left Ventricle Cardiomyopathy
7.5.4. Group 3 - Pulmonary Hypertension Secondary to Lung Diseases and Hypoxia 
7.5.5. Group 4 - Chronic Thromboembolic Pulmonary Hypertension and Other Pulmonary Artery Obstructions
7.5.6. Group 5 - Pulmonary Hypertension of Unestablished and/or Multifactorial Mechanism

7.6. Therapeutic Management of Pulmonary Arterial Hypertension

7.6.1. PHT Group 1
7.6.2. PHT Group 2
7.6.3. PHT Group 3
7.6.4. PHT Group 4
7.6.5. PHT Group 5

7.7. Hemoptysis.

7.7.1. Epidemiology, Etiology
7.7.2. Differential Diagnosis
7.7.3. Diagnostic Management
7.7.4. Treatment
7.7.5. Prognosis

7.8. Pulmonary Vasculitis

7.8.1. Epidemiology and Etiopathogenesis
7.8.2. Classification. Specific Vasculitis According to the CHCC 2012 Classification
7.8.3. Diagnosis
7.8.4. Treatment
7.8.5. Prophylaxis
7.8.6. Prognosis

7.9. Alveolar Hemorrhage

7.9.1. Diagnosis of an Alveolar Hemorrhage

7.9.1.1. Pathologic Anatomy/Pathogenesis
7.9.1.2. Differential Diagnosis

7.9.2.     Treatment

7.10. Intrapulmonary Shunts

7.10.1. Hepatopulmonary Syndrome
7.10.2. Arteriovenous Fistulae

Module 8. Respiratory Disorders During Sleep

8.1. Physiology and Epidemiology

8.1.1. Sleep Disorders Classification
8.1.2. Obstructive Sleep Apnea (OSA)
8.1.3. Pathophysiology.
8.1.4. Epidemiology
8.1.5. OSA as a Public Health Problem

8.2.  Risk Factors for OAS

8.2.1. Age and Sex
8.2.2. Obesity
8.2.3. Menopause
8.2.4. Craneofacial Anatomy and Heredity
8.2.5. Tabacco, Alcohol and Drugs
8.2.6. Supine Position

8.3. OAS and Comorbidities

8.3.1. OAS and Respiratory Diseases
8.3.2. AHT and Cardiovascular Risk
8.3.3. Endocrine Alterations
8.3.4. Neurological Alterations
8.3.5. Cancer

8.4. Clinical Manifestations of OSA

8.4.1. Symptoms and Signs
8.4.2. Physical Exploration
8.4.3. Complementary Evaluations
8.4.4. Criteria for Referral to the Sleep Unit

8.5. Diagnosis

8.5.1. Medical History
8.5.2. Polysomnography
8.5.3. Respiratory Polygraphy
8.5.4. Simplified Methods
8.5.5. Other Complementary Tests

8.6. Treatment

8.6.1. General Measures
8.6.2. Continuous Positive Airway Pressure (CPAP) Treatment
8.6.3. Other Modes of Positive Pressure: BPAP and Servoventilator
8.6.4. Different Positive Pressure Options

8.7.  OSA in Special Population Groups

8.7.1. Children and Adults
8.7.2. Elderly People
8.7.3. Women
8.7.4.  SA and Pregnancy

8.8. Central Apnea syndrome

8.8.1. Clinical manifestations
8.8.2. Diagnosis
8.8.3. Treatment

8.9. Hypoventilation Syndrome.

8.9.1. Classification of Alveolar Hypoventilation Syndromes
8.9.2. Obesity Hypoventilation Syndrome
8.9.3. Idiopathic Central Alveolar Hypoventilation
8.9.4. Congenital Central Alveolar Hypoventilation Syndrome
8.9.5. Hypoventilation During Sleep Related to Medication or Substances
8.9.6. Hypoventilation During Sleep Related to Medical Disorders

8.10. Other Sleep Disorders

8.10.1. Hypersomnias
8.10.2. Parasomnias and Restless Leg Syndrome
8.10.3. Insomnia and Drowsiness
 

Module 9. Respiratory Failure. Non-Invasive Mechanical Ventilation. High-Flow Oxygen Therapy

9.1. Respiratory Failure

9.1.1. According to Pathophysiology (Partial, Global, Postoperative or Hypoperfusion/Shock)

9.1.1.1. According to Time of Onset (Acute, Chronic and Acute Chronic)
9.1.1.2. According to Alveolar-Arterial Gradient (Normal or Elevated)
9.1.1.3. Pathophysiological Mechanisms

9.1.2. Decrease in Oxygen Partial Pressure

9.1.2.1. Presence of a Circuit Breaker or Shunt
9.1.2.2. Ventilation/Perfusion imbalance (V/Q)
9.1.2.3. Alveolar Hypoventilation
9.1.2.4. Diffusion Alteration

9.2.  Diagnosis

9.2.1. Clinical Symptoms
9.2.2. Arterial Blood Gas Analysis. Interpretation
9.2.3. Pulse Oximetry
9.2.4. Imaging Tests
9.2.5. Others: Respiratory Function Tests, ECG, Blood Analysis, etc.
9.2.6. Etiology of Respiratory Failure
9.2.7. Treatment of Respiratory Failure

9.2.7.1. General Measures
9.2.7.2. Oxygen Therapy, NIMV and HFO (See Next Sections)

9.3. Conventional Oxygen Therapy

9.3.1. Indications of Acute Oxygen Therapy
9.3.2. Indications for Chronic Home Oxygen Therapy
9.3.3. Systems and Sources of Administration
9.3.4. Oxygen Sources
9.3.5. Special Situations: Flights

9.4. Non-Invasive Mechanical Ventilation (NIMV)

9.4.1. Pathophysiological Effects

9.4.1.1. On the Respiratory System
9.4.1.2. On the Cardiovascular System

9.4.2. Components

9.4.2.1. Interfaces
9.4.2.2. Complications of the Interface: Skin Lesions, Leaks
9.4.2.3. Accessories

9.4.3. Monitoring

9.5. Indications and Contraindications NIMV

9.5.1. In the Acute Phase

9.5.1.1. In Emergency Situations Prior to Concrete Diagnosis
9.5.1.2. Acute Hypercapnic Respiratory Failure (Acute COPD, Decompensation of OHS Patient, Respiratory Center Depression, etc.)
9.5.1.3. Hypoxemic ARF de Novo/ARDS/Immunosuppressed
9.5.1.4. Neuromuscular Diseases
9.5.1.5. Post-Surgery
9.5.1.6. Weaning and Extubation
9.5.1.7. Patients Ordered Not to Intubate

9.5.2. In the Chronic Phase

9.5.2.1. COPD
9.5.2.2. Restrictive Diseases (Thoracic Wall, Diaphragm, Neuromuscular, etc)
9.5.2.3. Palliative Situation

9.5.3. Contraindications
9.5.4. NIMV Failure

9.6. Basic Concepts of NIMV

9.6.1. Respiratory Parameters of the Ventilator

9.6.1.1. Trigger
9.6.1.2. Cycling
9.6.1.3. Ramp
9.6.1.4. IPAP
9.6.1.5. EPAP
9.6.1.6. Pressure Support
9.6.1.7. PEEP
9.6.1.8. I/E Relationship

9.6.2. Interpretation of Respiratory Curves

9.7. Main Ventilatory Modes

9.7.1. Pressure-Limited

9.7.1.1. Continuous Positive Airway Pressure (CPAP) 
9.7.1.2. Bilevel Positive Airway Pressure (BIPAP)

9.7.2. Volume-Limited
9.7.3. New Modes: AVAPS, IVAPS, NAVA, Autotrack

9.8. Main Asynchronies

9.8.1. Due to Leakage

9.8.1.1. Autocycled
9.8.1.2. Prolonged Inspiration

9.8.2. Due to Ventilator

9.8.2.1. Short Cycle
9.8.2.2. Double Trigger
9.8.2.3. Ineffective Effort

9.8.3. Due to the Patient

9.8.3.1. AutoPEEP
9.8.3.2. Reverse Trigger

9.9. High-Flow Nasal Cannula Therapy (HFNCT)

9.9.1. Components
9.9.2. Clinical Effects and Mechanism of Action

9.9.2.1. Improvement in Oxygenation
9.9.2.2. Dead Space Lavage
9.9.2.3. PEEP Effect
9.9.2.4. Reduction in Respiratory Work
9.9.2.5. Hemodynamic Effects
9.9.2.6. Comfort

9.10. Clinical Applications and Contradictions of TAF

9.10.1. Clinical Applications

9.10.1.1. Acute Hypoxemic Respiratory Failure/ ARDS/ Immunosuppressed
9.10.1.2. Hypercapnic Respiratory Failure in COPD
9.10.1.3. Acute Heart Failure and Acute Pulmonary Edema
9.10.1.4. Invasive (Fibrobronchoscopy) and Post-Surgery Procedures
9.10.1.5. Pre-Oxygenation Prior to Intubation and Prevention of Post-Extubation Respiratory Failure
9.10.1.6. Patients in a Palliative Situation

9.10.2. Contraindications
9.10.3. Complications
 

Module 10. Lung Transplant

10.1. Lung Transplant

10.1.1. Historical Recollection
10.1.2. Evolution in Recent Years: Demographic Revision, Analysis by Pathologies and Survival

10.2. Selection of Receptors

10.2.1. Absolute Contra-indications
10.2.2. Relative Contra-indications
10.2.3. Indications for Referral to a Lung Transplant Unit Due to Pathologies

10.2.3.1. Usual Interstitial Pneumonia/ Non-Specific Interstitial Pneumonia
10.2.3.2. Chronic Obstructive Pulmonary Disease
10.2.3.3. Cystic Fibrosis
10.2.3.4. Pulmonary Hypertension

10.2.4. Indications for Referral to a Lung Transplant Unit Due to Pathologies

10.2.4.1. Usual Interstitial Pneumonia/ Non-Specific Interstitial Pneumonia
10.2.4.2. Chronic Obstructive Pulmonary Disease
10.2.4.3. Cystic fibrosis
10.2.4.4. Pulmonary Hypertension

10.3. Selection of Donor

10.3.1. Brain-Dead Donor
10.3.2. Donor in Asystole
10.3.3. Exvivo Evaluation System

10.4. Surgical Technique

10.4.1. Removal of the Affected Lung
10.4.2. Bench Surgery
10.4.3. Graft Implantation

10.5. Cardio-Respiratory Care

10.5.1. ECMO as a Bridge to a Transplant
10.5.2. Intra-Operative ECMO
10.5.3. Post-Operative Radiotherapy

10.6. Early Complications of Lung Transplants

10.6.1. Hyperacute Rejection
10.6.2. Primary Dysfunction of the Graft
10.6.3. Complications from Surgery
10.6.4. Peri-Operative Infections

10.7. Post-Operative Care

10.7.1. Immunosuppressive Treatments
10.7.2. Infectious Prophylaxis
10.7.3. Monitoring

10.8. Delayed Complications of Lung Transplants

10.8.1. Acute Cellular Rejection (Early or Delayed)
10.8.2. Chronic Dysfunction of the Graft. Chronic Lung Allograf Disfunction (CLAD)

10.8.2.1. Types
10.8.2.2. Treatment

10.8.3. Tumours

10.8.3.1. Cutaneous Tumors
10.8.3.2. Post-Transplant Lymphoproliferative Syndrome
10.8.3.3. Solid Tumors
10.8.3.4. Kaposi's Sarcoma

10.8.4. Infections
10.8.5. Other Frequent Complications

10.8.5.1. Diabetes Mellitus

10.8.5.2. Hyperlipidemia
10.8.5.3. High Blood Pressure
10.8.5.4. Acute and Chronic Kidney Failure

10.9. Quality of Life and Suffering

10.9.1. Quality of Life Analysis
10.9.2. Survival Rate; Evaluation of Subgroups

10.10. Re-Transplant

10.10.1. Indications and Limitations
10.10.2. Survival and Quality of Life

Module 11. Personalized Precision Medicine and Big Data in Pulmonology Prelude

11.1. Ethics in Precision Medicine
11.2. Advantages

11.2.1. Disadvantages of Precision Medicine

11.3. Precision Medicine as a Strategy
11.4. The Revolution of Precision Medicine 
11.5. Studies in Real Life

11.5.1. Advantages
11.5.2. Inconveniences

11.6. Pharmacogenomics
11.7. Proteomics
11.8. Chronicity

11.8.1. Personalization of Care

11.9. Telemedicine
11.10. Personalized Care for Dependents

11.10.1.The Role of Nursing Staff

Module 12. Interventional Pulmonology and Precision Medicine

12.1. EBUS-(Endobronchial Ultrasound)

12.1.1. Its Role in the Genetic Diagnosis and Most Precise Stadification of Lung Cancer

12.2. Radial Endobronchial Ultrasound (r-EBUS)

12.2.1. Its Role in the Diagnosis or Peripheral Lesions and the Genetic Typification of Lung Cancer

12.3. Electromagnetic Navigation

12.3.1. Its Role in the Diagnosis and Treatment of Peripheral Lesions

12.4. Narrow Band Imaging in Bronchoscopic Examination with Suspected Bronchial Neoplastic Disease
12.5. Endobronchial Therapy of Treatable Features

12.5.1. Homogeneous Emphysema with Intact Cysura

12.6. Endobronchial Therapy of Treatable Features Homogeneous Emphysema with Interlobar Communication
12.7. Endobronchial Therapy of Treatable Features

12.7.1. Non-Eosnophilic Asthma 

12.8. Detection of Diagnostic Markers in the Malignant Pleural Pathology With Minimally Invasive Techniques
12.9. Medical Thoracoscopy

12.9.1. Contribution to the Diagnostic Precision of Pleural Effusion
12.9.2. Alveoloscopy: "In Vivo" Analysis of the Peripheral Airways

Module 13. Precision Medicine, Imaging Techniques and Pulmonary Function

13.1. Quantification of Obstructive Pulmonary Impairment by Chest Computed Tomography Applied as a Tool for Increasing Diagnostic Accuracy
13.2. Lung Nodule Volumetry Applied as a Tool for Increasing Diagnostic Accuracy
13.3. Elastography of Lung Lesions

13.3.1. Pleurals as a Tool for Increasing Diagnostic Accuracy

13.4. Pleural Ultrasound Applied as a Tool to Increase Diagnostic Accuracy
13.5. Detection of Treatable Feature in Respiratory Diseases

13.5.1. Hyperinflation (Lung Volumes, Dynamic Hyperinflation)

13.6. Detection of Treatable Feature in Respiratory Diseases

13.6.1. Pulmonary Resistances
13.6.2. Peripheral Tract Involvement

13.7. Detection of Treatable Feature in Respiratory Diseases

13.7.1. Measurement of Physical Activity in the Personalization of Care and the Prognosis of Patients

13.8. Detection of Treatable Feature in Respiratory Diseases

13.8.1. Adherence to Treatment

13.9. Detection of Treatable Feature in Respiratory Diseases

13.9.1. Non-Invasive Detection of Bronchial Inflammation by Exhaled Nitric Oxide Fraction

13.10. Detection of Treatable Feature in Respiratory Diseases

13.10.1. Non-Invasive Detection of Bronchial Inflammation With Induced Sputum

Module 14. Genetics and Precision Medicine and Pediatric Diseases

14.1. Cystic Fibrosis Epidemiology

14.1.1. Genetic Basis

14.2. Cystic Fibrosis in Children

14.2.1. Manifestations

14.3. Cystic Fibrosis in Children

14.3.1. Screening and Treatment. Primary Ciliary Dyskinesia

14.4. Genetic Links of Respiratory Distress of the New Born

14.4.1. Bronchopulmonary Dysplasia

14.5. Duchenne and Becker Muscular Dystrophy

14.5.1. Genetic Basis

14.6. Duchenne and Becker Muscular Dystrophy

14.6.1. Management and Prosistic

14.7. Respiratory Involvement of Sickle Cell Disease
14.8. Underweight at Birth and Respiratory Disease
14.9. Treatments Oriented to Specific Therapeutic Targets in Childhood Asthma

14.9.1. Use of Biological Treatment in the Pediatric Population

Module 15. Genetics, Precision Medicine and Asthma

15.1. Epidemiology of Asthma

15.1.1. Familial, Racial or Generational Associations
15.1.2. Twin Studies

15.2. Genes Related to Asthma

15.2.1. Localization 1

15.3. Genes Related to Asthma

15.3.1. Localization 2

15.4. Inflammatory Pathways of Asthma
15.5. Precision Medicine in Asthma

15.5.1. Anti IgE Antibodies

15.6. Precision Medicine in Asthma

15.6.1. Anti IL-5 Antibodies or IL5 Receptor

15.7. Precision Medicine in Asthma

15.7.1. IL-4/IL-13 Antibodies

15.8. Precision Medicine and Other Biological Treatments in Asthma

15.8.1. Anti-IL-9, Anti-TNF Alpha, Anti-T-Lymphocyte Antibodies

15.9. Precision Medicine

15.9.1. Current and Future Biomarkers

15.10. Precision Medicine in Asthma

15.10.1. Linking Phenotypes to Specific Treatments

Module 16. Genetics, Precision Medicine and Lung Cancer

16.1. The Genetics of Lung Cancer Susceptibility

16.1.1. Implications for Treatment

16.2. Molecular Biology of Adenocarcinoma of the Lung

16.2.1. Driver Mutations

16.3. Molecular Biology of Squamous Cell Carcinoma of the Lung

16.3.1. Sarcomatoid Carcinoma of the Lung

16.4. Molecular Biology of Microcytic Carcinoma of the Lung
16.5. Genomic Platforms for Lung Cancer Molecular Diagnostics and Fluid Biopsy
16.6. Driver Mutations as Therapeutic Targets

16.6.1. EGFR Mutation

16.7. Driver Mutations as Therapeutic Targets

16.7.1. ALK Translocation

16.8. Driver Mutations as Therapeutic Targets

16.8.1. Others (ROS1, MET, RET, BRAF, NTRK)

16.9. Treatment Against Therapeutic Targets in Research

16.9.1. HER2, NRG1 y KRAS

16.10. Precision Medicine in Lung Cancer

16.10.1. Global Strategy for the Management of Lung Cancer Linked to Therapeutic Targets

Module 17. Genetics, Precision Medicine and COPD

17.1. Genetic Links of COPD
17.2. Genetic Alpha-1 Deficitiency

17.2.1. Antitrypsins

17.3. Epidemiology of Alpha- 1 Antitrypsin Deficiency
17.4. Manageemnt of Alpha 1 Antitrypsin Deficiency

17.4.1. Genetic Counselling Treatment

17.5. COPD and Underweight at Birth

17.5.1. COPD Trajectories

17.6. Genetics of Smoking
17.7. COPD Phenotypes

17.7.1. Bio Markers

17.8. Personalized Medicine

17.8.1. Treatment Oriented to Phenotypes

17.9. Sarcopenia

17.9.1. Intolerance to Exercise
17.9.2. Lack of Physical Activity
17.9.3. Sedentary Behavior

17.10. Association of Polymorphisms in ACTN3 Genes

17.10.1. ACE and PPARGC1A with the Effectiveness of Physical Training

Module 18. Genetics, Precision Medicine and Other Respiratory Diseases

18.1. Link Between Interstitial Lung Diseases and Genetics

18.2. Link Between Pulmonary Hypertension and Genetics
18.3. Genetic Basis of the Susceptibility of Hypoxemia in COPD
18.4. Genetic Disorders that Increase Susceptibility to Venous Thromboembolic Disease and Pulmonary Thromboembolism
18.5. Cystic Fibrosis in Adults

18.5.1. Suspected and Diagnosis 

18.6. Genetic Aspects of Obstructive Sleep Apnea Syndromes 
18.7. Telomeres and Respiratory Diseases
18.8. Genetic Variability in Susceptibility and Severity of Pneumonia
18.9. Genetic Variability in Susceptibility and Severity of Pneumonia
18.10. Vaccines Based on mRNA
18.10.1. Results and Secondary Effects in SARS-COVID-19 For Example

Module 19.  Big Data and Respiratory Diseases I

19.1. Big Data and Epidemiology of Respiratory Diseases

19.2. Big Data and Bronchoscopy
19.3. Big Data  and Non-invasive Mechanical Ventilation
19.4. Big Data and Invasive Mechanical Ventilation
19.5. Big Data and Smoking
19.6. Big Data and Air Pollution
19.7. Big Data and Asthma
19.8. Big Data and COPD
19.9. Big Data and Sleep Apnea-Hypopnea Syndrome
19.10. Big Data and Obesity-Hypoventilation Syndrome

Module 20.  Big Data and Respiratory Diseases II

20.1. Big Data y neumonía comunitaria 
20.2. Big Data e Infección nosocomial 
20.3. Big Data y tuberculosis 
20.4. Big Data, contaminación ambiental e Infección Respiratoria 
20.5. Big Data e Infección COVID-19 
20.6. Big Data, enfermedades de la pleura y cáncer de pulmón 
20.7. Big Data y enfermedades pulmonares intersticiales 
20.8. Big Data y enfermedad tromboembólica 
20.9. Big Data e hipertensión pulmonar 
20.10. Big Data y enfermedades respiratorias de inicio en el periodo neonatal 

A comprehensive specialized program that will take you through the necessary training to compete with the best in your profession”